Latest Clear Health Pass Wound Care News
CMS Confirms Government-to-Government Receipt of Tribal Real-World Evidence Submission for Rampart™ DL Matrix
The Centers for Medicare & Medicaid Services has issued formal Government-to-Government receipt confirmation for the Tribal Biotechnology & Health Consortium’s post-market clinical...
Tribal Consortium Commences Sovereign Enforcement Activity to Protect Tribal Authority Over the Rampart™ Product Line
Following the formal federal identification of Rampart™ DL Matrix (Q4347) as a tribally owned product in the December 15, 2025 CMS Federal Register publication, Clear Health Pass Holdings, in...
CMS Federal Register Identifies Rampart™ DL Matrix as Tribally Owned in CY 2026 Medicare Physician Fee Schedule Policy Update
The Centers for Medicare & Medicaid Services today published its CY 2026 Medicare Physician Fee Schedule Policy Update in the Federal Register, formally identifying Rampart™ DL Matrix...
Tribal Consortium Issues Sovereign Notice to CMS Requesting Formal Recognition of Tribal Ownership of Q4347
The Tribal Biotechnology & Health Consortium today transmitted a formal Sovereign Notice to the Centers for Medicare & Medicaid Services, accompanied by an ECHAGA Corporation Board...
CMS Coverage and Analysis Group Confirms Receipt of Tribal Real-World Evidence Submission
The Centers for Medicare & Medicaid Services Coverage and Analysis Group today confirmed receipt of the Tribal Biotechnology & Health Consortium’s post-market clinical validation submission...
Tribal Consortium Submits Post-Market Clinical Validation of Rampart™ DL Matrix to CMS as Government-to-Government Evidence
The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid...
A Statement on the Integrity of the Rampart™ Name and the Sovereign Authority of the Tribal Consortium
A STATEMENT FROM THE OFFICE OF THE CEO Issued by Clear Health Pass Holdings, LLC, as Authorized Tribal Agent It has come to the attention of Clear Health Pass Holdings, in its capacity as Authorized...
Rampart™ DL Matrix Issued on CMS Q4 2025 Average Sales Price File for Medicare Part B — 482 Days After Initial Sovereign Consultation
The Centers for Medicare & Medicaid Services has issued Rampart™ DL Matrix (HCPCS Q4347), the only FDA-cleared tribally owned skin substitute in the Medicare system, on the Q4 2025...
Tribal Consortium G2G Submission Posted Publicly on Regulations.gov
The Tribal Biotechnology & Health Consortium’s full sovereign submission on the CY 2026 Medicare Physician Fee Schedule has been posted publicly on Regulations.gov, the federal government’s...
Tribal Consortium Files Comment on CY 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P)
The Tribal Biotechnology & Health Consortium today filed its formal sovereign comment on the proposed CY 2026 Medicare Physician Fee Schedule (CMS-1832-P), continuing a coordinated, multi-docket...
Tribal Consortium Files Formal Comment on CY 2026 OPPS/ASC Proposed Rule (CMS-1834-P)
The Tribal Biotechnology & Health Consortium today filed its formal comment on the proposed CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System...
Clear Health Pass Appoints Dr. David Burke, MD, MA as Principal Investigator for Post-Market Clinical Validation of Rampart™ DL Matrix
Clear Health Pass Holdings, on behalf of the Tribal Biotechnology & Health Consortium, today announced the appointment of David Burke, MD, MA as Principal Investigator for the post-market...
Tribal Consortium Files 910-Page Substantive Comment on CY 2026 Medicare Physician Fee Schedule Proposed Rule
The Tribal Biotechnology & Health Consortium today filed a 910-page substantive comment with the Centers for Medicare & Medicaid Services on the proposed CY 2026 Medicare Physician Fee...
Clear Health Pass and CMS Coverage Group Convene Working Session on ASP and HCPCS Code Integrity for Q4347
The Tribal Consortium’s Authorized Tribal Agent, Clear Health Pass Holdings, joined a working session with CMS Drug Pricing and the Coverage and Analysis Group to address the Average Sales Price...
CMS Convenes Tribal Consultative Meeting on Rampart™ DL Matrix with Clear Health Pass and the Division of Tribal Affairs
The Centers for Medicare & Medicaid Services convened a formal Tribal Consultative Meeting with Clear Health Pass Holdings, Authorized Tribal Agent for the Tribal Biotechnology & Health...
Clear Health Pass Holdings Acquires Exclusive Worldwide Rights to Rampart™ DL Matrix as Authorized Tribal Agent
Clear Health Pass Holdings, LLC today completed its acquisition of exclusive worldwide commercial rights, administrative authority, and HCPCS Q-code holder responsibilities for Rampart™ DL...
Clear Health Pass Wound Care Partners with Tribal Leaders to Combat Diabetes Crisis in Native American Communities
Hollywood, FL – October 18, 2024 – Clear Health Pass Wound Care (CHP WC), in collaboration with a consortium of tribal leaders, is launching a comprehensive initiative to address the growing...
Clear Health Pass Presents Tribal Sovereign Framework to CMS and Novitas Solutions Policy Team
The Tribal Consortium, represented by Clear Health Pass Holdings, joined Centers for Medicare & Medicaid Services policy leadership and Novitas Solutions — the Medicare Administrative Contractor...
Tribal Consortium Submits Joint LCD Guidance to CMS on Skin Substitute Coverage Policy
On June 6, 2024, the Tribal Biotechnology & Health Consortium — through its founding partner, Blue Lake Rancheria Economic Development Corporation — submitted formal comments to the Centers for...